REG - IXICO plc - New contract win and contract extension

IXICOAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251015:nRSO3044Da&default-theme=true

RNS Number : 3044D  IXICO plc  15 October 2025

IXICO plc

("IXICO", the "Company" or the "Group")

 

New blood based biomarker contract win and

contract extension worth a total of £1.2 million.

 

 

15 October 2025 IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in
neuroscience imaging and biomarker analytics, using its AI-driven platform to
help advance drug development in neurological disorders, today announced that
it has signed a new commercial contract to assist in the validation of a
diagnostic blood test, reaffirming the Company's expertise in this area.
IXICO has also entered into a contract extension on an existing Alzheimer's
Disease (AD) clinical trial.  The combined value of the new contract and
contract extension is c. £1.2 million.

 

The new contract, with a leading global biopharma company, will run over a
contract period of under three years and will use IXICO's platform to
facilitate the analysis of a prospective blood-based biomarker test to aid the
diagnosis of a non-disclosed neurodegenerative disease.  The contract
extension adds a range of activities to an existing AD clinical trial being
supported by IXICO over the next few years.  This significant extension
reflects a series of smaller scope additions with existing biopharma clients
over the last couple of months and provides additional strength to IXICO's
long term order book.

 

The positive commercial momentum continues IXICO's successful execution of its
'Innovate, Lead, Scale' strategy to drive global expansion and growth.

 

Bram Goorden, CEO of IXICO, commented: "The new contract win marks our
continued expansion and expertise in the blood-based biomarker field. The
sustained period of contract extensions culminating in this important AD
clinical trial, demonstrates the demand for IXICO's services and expertise,
the consistent quality of our work, and the value we provide to major
biopharma clients."

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit)
Regulations 2019. Upon the publication of this announcement via the Regulatory
Information Service, this inside information is now considered to be in the
public domain.

Ends

 

For further information please contact:

 IXICO plc                                   +44 (0) 20 3763 7499
 Grant Nash, Chief Financial Officer

 James Chandler, Chief Business Officer

 Cavendish Capital Markets Limited           +44 (0) 20 7220 0500

 (Nominated Adviser and Sole Broker)
 Giles Balleny (Corporate Finance)

 Nigel Birks (Healthcare Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson (Sales)

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is a global leader in neuroscience imaging and biomarker analytics,
using its proprietary AI-driven platform to help advance the treatment of
neurological disorders and reduce the uncertainties associated with drug
discovery, development and monitoring.   As a key part of the global
neurological disease research community, the Company has built a global
reputation and 20-year track record as an end-to-end Imaging Contract Research
Organisation (iCRO) working with leading pharma companies, innovative
biotech's, disease consortia and non-profit organisations. IXICO has supported
hundreds of neurological clinical trials, analysed hundreds of thousands scans
and built an expansive network of expert imaging centres around the world.

 

The IXICO Platform is tailor-made for neurological disease, reliably
processing data from global trials, precisely measuring key imaging biomarkers
associated with the identification, progression and treatment of diseases such
as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by
the Platform and IXICO's expert scientists translating complex data into
clinically meaningful while minimizing data variability and increasing
reproducibility.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTEANELFSNSFEA



            Copyright 2019 Regulatory News Service, all rights reserved